ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings
  • Abstract Number: 2533 • ACR Convergence 2023

    Real-world Evidence for Assessing Mortality Disparity Between the Patients with Rheumatoid Arthritis and the General Population in Japan: Results from the IORRA Study

    Naohiro Sugitani1, Eiichi Tanaka2, Eisuke Inoue3, Mai Abe1, Eri Sugano1, Kumiko Saka1, Moeko Ochiai4, Rei Yamaguchi1, Katsunori Ikari5, Ayako Nakajima6, Hisashi Yamanaka7 and Masayoshi Harigai8, 1Division of Rheumatology, Department of Internal Medicine, Tokyo Women’s Medical University School of Medicine, Shinjunku-ku, Japan, 2Division of Rheumatology, Department of Internal Medicine, Tokyo Women's Medical University School of Medicine, Tokyo, Japan, 3Research Administration Center, Showa University, Shinagawa-ku, Japan, 4Division of Rheumatology, Department of Internal Medicine, Tokyo Women’s Medical University School of Medicine,, Shinjunku-ku, Japan, 5Tokyo Women's Medical University School of Medicine, Tokyo, Japan, 6Center for Rheumatic Diseases, Mie University Hospital, Tsu city, Japan, 7Sanno Medical Center, Tokyo, Japan, 8Tokyo Women's Medical University, Division of Rheumatology, Department of Internal Medicine, Tokyo, Japan

    Background/Purpose: Patients with rheumatoid arthritis (RA) have been reported to have higher mortality rates than the general population. Our previous report showed that the standardized…
  • Abstract Number: PP03 • ACR Convergence 2023

    Lupus with Slime: Improve QOL and Increase ROM in SLE with Slime

    Amanda Greene, Los Angeles, CA

    Background/Purpose: In 1983, over forty years ago, I was diagnosed with Systemic Lupus Erythematosus (SLE).  I was immediately prescribed high dose corticosteroids.  My body and…
  • Abstract Number: 2604 • ACR Convergence 2023

    Premature Vascular Smooth Muscle Cells Senescence Driven by Interleukin-6-Mitochondrial STAT3-Mitofusin 2 Signaling in Takayasu’s Arteritis

    Chenglong Fang1, Lihong Du1, Lili Li2, Yuexin Chen3, Zuoguan Chen4, Yongjun Li4, Jing Li1, Mengtao Li5, xiaofeng Zeng6 and Xinping Tian5, 1Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, China, 2The State Key Laboratory of Medical Molecular Biology, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences and School of Basic Medicine, Peking Union Medical College, Beijing, China, 3Department of Vascular Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, China, 4Department of Vascular Surgery, Beijing Hospital, National Center of Gerontology; Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, China, 5Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China, 6Department of Rheumatology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China

    Background/Purpose: Takayasu’s arteritis (TAK) is characterized by persistent vascular inflammation involving aorta and its main branches, which is an important prosenescent factor that in turn…
  • Abstract Number: PP07 • ACR Convergence 2023

    How “Coming Out” About My Lupus Diagnosis Allowed Me to Connect With Patients, Get Involved With Research, and Spread Awareness

    Jamie Chieh Lo, School of Medicine, I-Shou University, Keelung, Taiwan

    Background/Purpose: Ever since I started medical school, I have been advised to not talk about my experiences with SLE. Family, friends, and even professors have…
  • Abstract Number: 2545 • ACR Convergence 2023

    Efficacy and Safety of Intravenous Secukinumab for the Treatment of Active Axial Spondyloarthritis: Results from a Randomized, Double-Blind, Phase 3 Study

    Atul Deodhar1, Jerzy Supronik2, Alan Kivitz3, Guillermo Valenzuela4, Karen Kapur5, Susanne Rohrer6, Eva Dokoupilova7, Hanno Richards6 and Karel Pavelka8, 1Division of Arthritis and Rheumatic Disease, Oregon Health & Science University, Portland, OR, 2OsteoMedic sc A Racewicz J Supronik, Bialystok, Poland, 3Altoona Center for Clinical Research, Duncansville, PA, 4Integral Rheumatology & Immunology Specialists, Plantation, FL, 5Novartis Pharmaceuticals Corporation, East Hanover, NJ, 6Novartis Pharma AG, Basel, Switzerland, 7Masaryk University, Faculty of Pharmacy, Department of Pharmaceutical Technology; MEDICAL PLUS sro, Brno, Czech Republic, 8Institut of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Praha, Czech Republic

    Background/Purpose: While subcutaneous secukinumab (SEC) is approved for the treatment of axial spondyloarthritis (axSpA), some patients may benefit more from intravenous (IV) administration. This study…
  • Abstract Number: 2521 • ACR Convergence 2023

    Understanding Age as a Risk Factor for Complications After Total Knee Arthroplasty: What Can We Learn from Machine Learning?

    Bella Mehta1, Yi Yiyuan2, Chloe Heiting3, Kaylee Ho2, Susan Goodman3, Peter Sculco3, Fei Wang2, Rich Caruana4, Peter cram5 and Said Ibrahim6, 1Hospital for Special Surgery, Weill Cornell Medicine, New York, NY, 2Weill Cornell Medicine, New York, NY, 3Hospital for Special Surgery, New York, NY, 4Microsoft, Redmond, WA, 5The University of Texas Medical Branch, Galveston, TX, 6Northwell Health, New Hyde Park, NY

    Background/Purpose: Rates of total knee arthroplasty (TKA) in the United Stateshave risen, coupled with increasing demand for TKAs in younger patients.1Althoughrates of postoperative complications in…
  • Abstract Number: 2539 • ACR Convergence 2023

    Baseline IL-10 Levels as a Predictive Biomarker for Achieving Clinical Response with Abatacept in ACPA+ Patients with Early RA

    Jinqi Liu1, Yicong Li2, Kai Fu1, Chun Wu1, Peter Schafer3, Sean Connolly1, Ian M. Catlett4, Michael Maldonado1, Robert Wong5, Paul Emery6, Yoshiya Tanaka7, Vivian Bykerk8, Clifton Bingham9, Thomas Huizinga10 and Roy Fleischmann11, 1Bristol Myers Squibb, Princeton, NJ, 2Parexel International, Durham, NC, 3Bristol Myers Squibb, Belle Mead, NJ, 4Bristol Myers Squibb, Pennington, NJ, 5Bristol Myers Squibb (at the time of analysis), Princeton, NJ, 6Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, and NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, 7University of Occupational and Environmental Health, Kitakyushu, Japan, 8Department of Rheumatology, Hospital for Special Surgery, New York, NY, 9Division of Rheumatology, Department of Medicine, Johns Hopkins University, Baltimore, MD, 10Leiden University Medical Center, Leiden, Netherlands, 11Division of Rheumatology, University of Texas Southwestern Medical Center, Metroplex Clinical Research Center, Dallas, TX

    Background/Purpose: A key target of RA treatment is to achieve early and sustained remission in order to ensure lower levels of long-term structural joint damage…
  • Abstract Number: 2536 • ACR Convergence 2023

    DMARD Adherence During the COVID-19 Pandemic and Association with Risk of COVID-19 Infection

    Tanya Selvam, Kelli Peterman, Arezoo Haghshenas and Lucy Liu, Kaiser Permanente Northern California, Oakland, CA

    Background/Purpose: The COVID-19 pandemic affected medication adherence in patients with autoimmune disease (AD) due to their fear of contracting COVID-19, financial hardship, and medication shortage.…
  • Abstract Number: PP08 • ACR Convergence 2023

    Finding Gratitude in Adversity: The Impact of Finding the Right Rheumatologist

    Yaideliz Acevedo, Global Healthy Living Foundation, Newark, NJ

    Background/Purpose: I recall sitting in the doctor's office with my one-month-old baby in his stroller, hearing the words "You have rheumatoid arthritis." At 21, I…
  • Abstract Number: PP02 • ACR Convergence 2023

    Patient Centered Care: The Complete Picture

    Chisa Nosamiefan, South Weymouth, MA

    Background/Purpose: My recollection is that in I997 there about, I began to feel sick and I experienced these symptoms, night sweats, pain in my chest,…
  • Abstract Number: PP09 • ACR Convergence 2023

    Practicing Mindfulness to Improve Quality of Life

    Vanessa Patino-Lydia, Global Healthy Living Foundation, Hallandale, FL

    Background/Purpose: I’ve been living with symptoms of PSA and fibromyalgia for over 15 years. Four years ago, after flareup that severely impacted my mobility where…
  • Abstract Number: PP01 • ACR Convergence 2023

    You Can’t Get This from a Doctor: The Role of Support Groups for Adults Aged 25-55 Living with Arthritis

    Eileen Davidson, Global Healthy Living Foundation, Burnaby, BC, Canada

    Background/Purpose: Living with a rheumatic condition comes with unique concerns specific to mental and social health like struggling with fatigue, anxiety, depression, and isolation, all…
  • Abstract Number: 2449 • ACR Convergence 2023

    Cognitive Functioning Among Individuals with Systemic Lupus Erythematosus: A Population-Based Study

    Laura Plantinga1, C. Barrett Bowling2, Charmayne Dunlop-Thomas1, Courtney Hoge1, Bradley Pearce1, Cristina Drenkard1 and S. Sam Lim1, 1Emory University, Atlanta, GA, 2Duke University, Durham, NC

    Background/Purpose: Studies of objectively measured cognitive dysfunction in SLE are often limited by small sample size, limited generalizability, and lack of diversity. We sought to…
  • Abstract Number: 2086 • ACR Convergence 2023

    From Fellow to Fellowship Director: Gender Equity in Pediatric Rheumatology Pipeline

    Bessie Roca loor1, Maya Pandit2, Tracey Wright3 and Mill Etienne4, 1New York Medical College, Yonkers, NY, 2Columbia University, New York, NY, 3UT Southwestern, Dallas, TX, 4New York Medical College, Valhalla, NY

    Background/Purpose: As the demand for pediatric rheumatologists rise across the United States with a projected demand of almost 100% more pediatric rheumatologists needed by 2030…
  • Abstract Number: 0401 • ACR Convergence 2023

    Resolution of Swollen Joint Count Is an Important Clinical Objective in Early Rheumatoid Arthritis : Analysis of the UCLouvain Brussels ERA Cohort and Comparison with the Remission Composite Index

    Francesco Natalucci1, clement triaille2, Emilie Sapart2, Laura BRICMAN3, Cécile VAN MULLEM2, Charlotte Desmet2, Stéphanie DIERCKX4, Marie DOYEN2, Tatiana Sokolova5, Aleksandra AVRAMOVSKA3 and Patrick Durez2, 1UCLouvain University, Sermoneta, Italy, 2Cliniques Universitaires Saint-Luc – Université catholique de Louvain (UCLouvain) – Institut de Recherche Expérimentale et Clinique (IREC), Rheumatology, Brussels, Belgium, 3Rheumatology, Cliniques Universitaires Saint-Luc – Université catholique de Louvain (UCLouvain) – Institut de Recherche Expérimentale et Clinique (IREC), Brussels, Belgium, 4CHU UCL Namur, Rheumatology, Mont-Godinne, Belgium, Mont Godinne, Belgium, 5Université Catholique de Louvain, Brussels, Belgium

    Background/Purpose: Rheumatoid Arthritis is a chronic autoimmune disease characterized by persistent joint inflammation. According to international guidelines, the treatment target should aim to reach the…
  • « Previous Page
  • 1
  • …
  • 468
  • 469
  • 470
  • 471
  • 472
  • …
  • 2605
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology